CF PharmTech Receives NMPA Acceptance for First-in-Class Inhaled Pulmonary Fibrosis Treatment ICF004
Key Insights
CF PharmTech (search) announced that China's NMPA has accepted the IND application for ICF004 (search), a first-in-class inhaled dry powder candidate targeting progressive fibrosing interstitial lung disease (search).
The drug is designed to deliver medication directly to lung lesions while minimizing systemic exposure, potentially addressing the efficacy-tolerability challenges of current oral therapies.
Preclinical studies demonstrated significant exposure differential between lung tissue and blood, with anti-fibrotic activity trends observed in animal models.
CF PharmTech (search), Inc. (HKEX: 2652.HK) announced that China's National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for ICF004 (search), the company's internally developed first-in-class inhaled dry powder candidate for treating progressive fibrosing interstitial lung disease (search) (PF-ILD). The acceptance marks a significant milestone for the Suzhou-based company's innovative respiratory drug development platform.
Targeting Critical Unmet Medical Need
ICF004 (search) is intended for the treatment of PF-ILD, a disease category encompassing life-threatening conditions such as idiopathic pulmonary fibrosis (search) (IPF) and progressive pulmonary fibrosis (search) (PPF). These conditions are characterized by progressively worsening respiratory symptoms and irreversible decline in lung function, with generally poor prognosis.
Using IPF as a representative condition, publicly available data indicate a median survival of approximately 2.8 years and a 5-year survival rate below 40%, underscoring the substantial clinical burden of disease. While oral therapies have been approved globally for IPF treatment, public clinical data and real-world evidence suggest that existing therapies may only slow decline in lung function to some extent, with some patients still facing limited survival benefit, significant adverse-event burden, and treatment interruption or discontinuation.
Novel Delivery Approach for Enhanced Therapeutic Window
ICF004 (search) employs an inhaled dry powder delivery route designed to deliver medication directly to lung lesion areas, thereby increasing local pulmonary exposure while minimizing systemic exposure. This approach aims to achieve a better balance between efficacy and safety compared to current oral treatments.
The company positions ICF004 (search) as a candidate integrating mechanism exploration and formulation innovation, conducting mechanistic research and translational validation around fibrosis-related pathological processes, including inflammation, oxidative stress, and fibroblast activation.
Promising Preclinical Results
According to CF PharmTech (search)'s completed preclinical studies, ICF004 (search) demonstrated differentiated distribution characteristics between lung tissue exposure and systemic blood exposure following inhaled administration. The company observed a significant exposure differential between lung and blood, supporting the project's development strategy centered on improving target-organ exposure efficiency and reducing systemic exposure burden through local targeted delivery.
Additionally, the company observed anti-fibrotic activity trends for ICF004 (search) in relevant preclinical models. These findings provide supportive information for subsequent clinical development, though whether they will translate into clinical efficacy and safety advantages in humans remains to be verified in future clinical trials.
Platform Validation and Strategic Significance
The IND acceptance represents the first time one of CF PharmTech (search)'s innovative drug programs has entered the regulatory acceptance stage. The company believes this progress validates its platform translational capability, demonstrating its ability to integrate complex formulations, delivery systems, device engineering, and unmet clinical needs in advancing innovative drug development programs.
The milestone also strengthens the replicability of the company's R&D pathways, providing methodological and organizational experience for subsequent innovative programs in respiratory and related therapeutic areas. Furthermore, it enhances capital market understanding of CF PharmTech (search)'s platform-based capabilities beyond complex formulation business alone.
Regulatory Details and Next Steps
The IND application falls under Class 1 chemical drug candidate registration, with acceptance numbers CXHL2600132 and CXHL2600133. The applicant is Changfeng Suyue Pharmaceutical (search) (Guangzhou) Co., Ltd., a subsidiary of CF PharmTech (search).
CF PharmTech (search) will continue to advance subsequent clinical development activities for ICF004 (search) in accordance with NMPA requirements, including clinical start-up preparation, subject enrollment arrangements, and phased data readouts. The company will also evaluate strategic pathways such as independent development and collaborative development based on the project's clinical progress, resource allocation, and external partnership opportunities.
Risk Considerations
The company emphasizes that innovative drug R&D involves high investment, long development timelines, and significant risks. Uncertainties remain in the subsequent clinical development, regulatory review and approval, and commercialization process of ICF004 (search). The IND acceptance is an administrative step and not a marketing approval, with no guarantee of eventual market authorization.